title: Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma.
abstract: OBJECTIVE
  To describe a case series of neovascular glaucoma (NVG) caused by central retinal vein occlusion (CRVO) that was treated with intravitreal bevacizumab (IVB; Avastin).
  
  
  METHODS
  Retrospective interventional case series.
  
  
  METHODS
  Six consecutive patients with NVG and a refractory, symptomatic elevation of intraocular pressure (IOP) and pronounced anterior segment congestion received IVB (1.25 mg/0.05 ml). Diode laser cyclophotocoagulation was carried out only if pressure was controlled insufficiently by topical medication. Follow-up examinations occurred at four to 16 weeks.
  
  
  RESULTS
  IVB resulted in a marked regression of anterior segment neovascularization and relief of symptoms within 48 hours. IOP decreased substantially in three eyes; in the other three eyes, adjuvant cyclophotocoagulation was necessary. No side effects were observed. Panretinal photocoagulation (PRP) was performed as soon as feasible, five to 12 weeks after IVB treatment.
  
  
  CONCLUSIONS
  IVB leads to a rapid regression of iris and angle neovascularization and should be investigated more thoroughly as an adjunct in the management of NVG.
authors.affiliation: Department of Ophthalmology, University of Bern, Inselspital, Bern, Switzerland. milko.lliev@insel.ch
authors.forename: Milko E
authors.initials: ME
authors.lastname: Iliev
authors.forename: Diego
authors.initials: D
authors.lastname: Domig
authors.forename: Ute
authors.initials: U
authors.lastname: Wolf-Schnurrbursch
authors.forename: Sebastian
authors.initials: S
authors.lastname: Wolf
authors.forename: Gian-Marco
authors.initials: GM
authors.lastname: Sarra
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005260:Female; D015355:Glaucoma, Neovascular / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects; D007498:Iris / Q000601:surgery; D017075:Laser Coagulation; D008297:Male; D012170:Retinal Vein Occlusion / Q000150:complications; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab